1199773-09-5 Usage
Uses
Used in Chemical Synthesis:
4-(5-Bromo-3-chloropyridin-2-yl)morpholine is used as a chemical intermediate for the synthesis of other compounds. Its bromine and chlorine substituents can be utilized in various chemical reactions, making it a valuable component in the production of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-(5-Bromo-3-chloropyridin-2-yl)morpholine is used as a building block for the development of new drugs. Its unique structure and reactivity can be exploited to create novel molecules with potential therapeutic applications.
Used in Agrochemical Industry:
4-(5-Bromo-3-chloropyridin-2-yl)morpholine is used as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its versatility in chemical reactions allows for the creation of new compounds with improved efficacy and selectivity in controlling pests and weeds.
Used in Research and Development:
In the field of research and development, 4-(5-Bromo-3-chloropyridin-2-yl)morpholine is used as a model compound to study the effects of bromine and chlorine substitutions on the reactivity and properties of pyridine derivatives. This can lead to a better understanding of the underlying chemistry and the development of new synthetic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 1199773-09-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,9,7,7 and 3 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1199773-09:
(9*1)+(8*1)+(7*9)+(6*9)+(5*7)+(4*7)+(3*3)+(2*0)+(1*9)=215
215 % 10 = 5
So 1199773-09-5 is a valid CAS Registry Number.
1199773-09-5Relevant articles and documents
SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF
-
Paragraph 1025-1026, (2020/02/19)
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.